ArticleMicrobial cell factories2020
Rational engineering of Kluyveromyces marxianus to create a chassis for the production of aromatic products.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Expanding the Genetic Toolkit of Pichia kudriavzevii E1 for Enhanced Mycoprotein Production.Microbial biotechnology · 2026Article
- Synergistic Growth and Metabolic Interactions ofMetabolites · 2026Article
- Reprogramming a Hgt-family Kluyveromyces marxianus sugar transporter by site-directed mutagenesis to enable co-consumption of glucose and xylose.FEMS yeast research · 2026Article
- EngineeringFrontiers in microbiology · 2026Review
- Endogenous pathway dysregulation in Kluyveromyces marxianus under nitrogen limitation drives 2-phenylethyl acetate and 2-phenylethanol overproduction.Scientific reports · 2025Article
- Computational biology predicts metabolic engineering targets for increased production of 103 valuable chemicals in yeast.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- From genetic constraints to process hurdles: A review ofCurrent research in food science · 2025Review
- Screening of broad-host expression promoters for shuttle expression vectors in non-conventional yeasts and bacteria.Microbial cell factories · 2024Article
- RNA polymerase II-driven CRISPR-Cas9 system for efficient non-growth-biased metabolic engineering ofMetabolic engineering communications · 2022Article
- Protein engineering for feedback resistance in 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase.Applied microbiology and biotechnology · 2022Article
- Metabolic engineering of3 Biotech · 2022Article
- Development of a ribosome profiling protocol to study translation in Kluyveromyces marxianus.FEMS yeast research · 2022Article
- Identification of a novel gene required for competitive growth at high temperature in the thermotolerant yeastMicrobiology (Reading, England) · 2022Article
- Protocols for marker-free gene knock-out and knock-down in Kluyveromyces marxianus using CRISPR/Cas9.FEMS yeast research · 2022Article
- Unraveling the potential of non-conventional yeasts in biotechnology.FEMS yeast research · 2022Article
- BioprospectingFrontiers in bioengineering and biotechnology · 2022Review
- Identification of novel pentose transporters in Kluyveromyces marxianus using a new screening platform.FEMS yeast research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe yeast Kluyveromyces marxianus offers unique potential for industrial biotechnology because of useful features like rapid growth, thermotolerance and a wide substrate range. As an emerging alternative platform, K. marxianus requires the development and validation of metabolic engineering strategies to best utilise its metabolism as a basis for bio-based production.
resultsTo illustrate the synthetic biology strategies to be followed and showcase its potential, we describe a comprehensive approach to rationally engineer a metabolic pathway in K. marxianus. We use the phenylalanine biosynthetic pathway both as a prototype and because phenylalanine is a precursor for commercially valuable secondary metabolites. First, we modify and overexpress the pathway to be resistant to feedback inhibition so as to overproduce phenylalanine de novo from synthetic minimal medium. Second, we assess native and heterologous means to increase precursor supply to the biosynthetic pathway. Finally, we eliminate branch points and competing reactions in the pathway and rebalance precursors to redirect metabolic flux to a specific product, 2-phenylethanol (2-PE). As a result, we are able to construct robust strains capable of producing over 800 mg L
conclusionsThe strains we constructed are a promising platform for the production of aromatic amino acid-based biochemicals, and our results illustrate challenges with attempting to combine individually beneficial modifications in an integrated platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.